Hyphens Pharma licenses shingles drug from Maruho for ASEAN

6 June 2024

Singaporean speciality pharma company Hyphens Pharma International has entered into an exclusive license, development and commercialization agreement with Japanese drugmaker Maruho.

The deal will provide Hyphens with exclusive rights to register and commercialize Amenalief (amenamevir) Tab 200mg tablets in the 10 ASEAN countries for the treatment of herpes zoster, also known as shingles, and recurrent herpes simplex.

Shingles is a viral infection caused by a reactivation of the dormant chickenpox varicella-zoster or VZV virus. Shingles strikes when a person’s immunity is weak and often manifests as a blistering and painful rash. In Singapore, more than 90% of adults over 50 years old carry the VZV virus and older persons are at higher risk of developing shingles. The main treatment for shingles is anti-viral medications like Amenalief.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK